Diagnosis and treatment of primary adrenal insufficiency: An endocrine society clinical practice guideline

Journal of Clinical Endocrinology and Metabolism

Volumn 101, Issue 2, 2016, Pages 364-389

  Bornstein, Stefan R ^a   Allolio, Bruno ^a   Arlt, Wiebke ^a   Barthel, Andreas ^a   Don Wauchope, Andrew ^a   Hammer, Gary D ^a   Husebye, Eystein S ^a   Merke, Deborah P ^a   Murad, M Hassan ^a   Stratakis, Constantine A ^a   Torpy, David J ^a  

^a Harvard Medical School   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOTROPIN; CORTISONE ACETATE; FLUDROCORTISONE; GLUCOCORTICOID; HYDROCORTISONE; PRASTERONE; PREDNISOLONE;

ADRENAL CORTEX INSUFFICIENCY; ADRENAL INSUFFICIENCY; ARTICLE; CLINICAL FEATURE; CORTICOTROPIN TEST; DRUG MONITORING; EVIDENCE BASED PRACTICE; FLUID RESUSCITATION; HORMONE SUBSTITUTION; HUMAN; HYDROCORTISONE BLOOD LEVEL; LABORATORY TEST; LIBIDO; PATIENT CARE; PRACTICE GUIDELINE; PREGNANCY; PRIORITY JOURNAL; QUALITY OF LIFE; THERAPY DELAY; EVIDENCE BASED MEDICINE; FEMALE; MEDICAL SOCIETY; PROCEDURES;

ADRENAL INSUFFICIENCY; EVIDENCE-BASED MEDICINE; FEMALE; HORMONE REPLACEMENT THERAPY; HUMANS; PREGNANCY; SOCIETIES, MEDICAL;

EID: 84959422964     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2015-1710     Document Type: Article

References (181)

1. Addison T. On the Constitutional and Local Effects of Disease of the Supra-renal Capsules. London, UK: Samuel Highley; 1855.
2. Bleicken B, Hahner S, Ventz M, Quinkler M. Delayed diagnosis of adrenal insufficiency is common: a cross-sectional study in 216 patients. Am J Med Sci. 2010;339:525-531.
3. Løvås K, Loge JH, Husebye ES. Subjective health status in Norwegian patients with Addison's disease. Clin Endocrinol (Oxf). 2002;56:581-588.
4. Hahner S, Allolio B. Therapeutic management of adrenal insufficiency. Best Pract Res Clin Endocrinol Metab. 2009;23:167-179.
5. Reisch N, Arlt W. Fine tuning for quality of life: 21st century approach to treatment of Addison's disease. Endocrinol Metab Clin North Am. 2009;38:407-418, ix-x.
6. Meyer G, Hackemann A, Penna-Martinez M, Badenhoop K. What affects the quality of life in autoimmune Addison's disease? Horm Metab Res. 2013;45:92-95.
7. ErichsenMM,Løvås K, Fougner KJ, et al. Normal overall mortality rate in Addison's disease, but young patients are at risk of premature death. Eur J Endocrinol. 2009;160:233-237.
8. Wallace I, Cunningham S, Lindsay J. The diagnosis and investigation of adrenal insufficiency in adults. Ann Clin Biochem. 2009; 46:351-367.
9. Chakera AJ, Vaidya B. Addison disease in adults: diagnosis and management. Am J Med. 2010;123:409-413.
10. Laureti S, Vecchi L, Santeusanio F, Falorni A. Is the prevalence of Addison's disease underestimated? J Clin Endocrinol Metab. 1999; 84:1762.
11. Meyer G, Neumann K, Badenhoop K, Linder R. Increasing prev-alence of Addison's disease in German females: health insurance data 2008-2012. Eur J Endocrinol. 2014;170:367-373.
12. Bornstein SR. Predisposing factors for adrenal insufficiency. N Engl J Med. 2009;360:2328-2339.
13. Grossman AB. Clinical review: The diagnosis and management of central hypoadrenalism. J Clin Endocrinol Metab. 2010;95:4855-4863.
14. Speiser PW, Azziz R, Baskin LS, et al. Congenital adrenal hyperplasia due to steroid 21-hydroxylase deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2010; 95:4133-4160.
15. Atkins D, Best D, Briss PA, et al. GraDing quality of evidence and strength of recommendations. BMJ. 2004;328:1490.
16. Swiglo BA, Murad MH, Schünemann HJ, et al. A case for clarity, consistency, and helpfulness: state-of-the-art clinical practice guidelines in endocrinology using the graDing of recommendations, assessment, development, and evaluation system. J Clin Endocrinol Metab. 2008;93:666-673.
17. Guyatt GH, Schünemann HJ, Djulbegovic B, Akl EA. Guideline panels should not GRADE good practice statements. J Clin Epidemiol. 2015;68:597-600.
18. Kazlauskaite R, Evans AT, Villabona CV, et al. Corticotropin tests for hypothalamic-pituitary-adrenal insufficiency: a metaanalysis. J Clin Endocrinol Metab. 2008;93:4245-4253.
19. Oelkers W, Boelke T, Bähr V. Dose-response relationships between plasma adrenocorticotropin (ACTH), cortisol, aldosterone, and 18-hydroxycorticosterone after injection of ACTH-(1-39) or human corticotropin-releasing hormone in man. J Clin Endocrinol Metab. 1988;66:181-186.
20. LeeMK,Vasikaran S, Doery JC, Wijeratne N, Prentice D. Cortisol: ACTH ratio to test for primary hypoadrenalism: a pilot study. Postgrad Med J. 2013;89:617-620.
21. Wood JB, Frankland AW, James VH, Landon J. A rapid test of adrenocortical function. Lancet. 1965;1:243-245.
22. Abdu TA, Elhadd TA, Neary R, Clayton RN. Comparison of the low dose short synacthen test (1 microg), the conventional dose short synacthen test (250 microg), and the insulin tolerance test for assessment of the hypothalamo-pituitary-adrenal axis in patients with pituitary disease. J Clin Endocrinol Metab. 1999;84:838-843.
23. Schmidt IL, Lahner H, Mann K, Petersenn S. Diagnosis of adrenal insufficiency: evaluation of the corticotropin-releasing hormone test and basal serum cortisol in comparison to the insulin tolerance test in patients with hypothalamic-pituitary-adrenal disease. J Clin Endocrinol Metab. 2003;88:4193-4198.
24. Deutschbein T, Unger N, Mann K, Petersenn S. Diagnosis of secondary adrenal insufficiency in patients with hypothalamic-pituitary disease: comparison between serum and salivary cortisol during the high-dose short synacthen test. Eur J Endocrinol. 2009; 160:9-16.
25. Cho HY, Kim JH, Kim SW, et al. Different cut-off values of the insulin tolerance test, the high-dose short Synacthen test (250 g) and the low-dose short Synacthen test (1 g) in assessing central adrenal insufficiency. Clin Endocrinol (Oxf). 2014;81:77-84.
26. Chatha KK, Middle JG, Kilpatrick ES. National UK audit of the short synacthen test. Ann Clin Biochem. 2010;47:158-164.
27. Reynolds RM, Stewart PM, Seckl JR, Padfield PL. Assessing the HPA axis in patients with pituitary disease: a UK survey. Clin Endocrinol (Oxf). 2006;64:82-85.
28. Grinspoon SK, Biller BM. Clinical review 62: Laboratory assessment of adrenal insufficiency. J Clin Endocrinol Metab. 1994;79: 923-931.
29. Dorin RI, Qualls CR, Crapo LM. Diagnosis of adrenal insufficiency. Ann Intern Med. 2003;139:194-204.
30. Gundgurthi A, Garg MK, Dutta MK, Pakhetra R. Intramuscular ACTH stimulation test for assessment of adrenal function. J Assoc Physicians India. 2013;61:320-324.
31. Bhansali A, Subrahmanyam KA, Talwar V, Dash RJ. Plasma cortisol response to 1 microgram adrenocorticotropin at 0800 h & 1600 h in healthy subjects. Indian J Med Res. 2001;114:173-176.
32. Dickstein G, Shechner C, Nicholson WE, et al. Adrenocorticotropin stimulation test: effects of basal cortisol level, time of day, and suggested new sensitive low dose test. J Clin Endocrinol Metab. 1991;72:773-778.
33. Charmandari E, Kino T. Chrousos syndrome: a seminal report, a phylogenetic enigma and the clinical implications of glucocorticoid signalling changes. Eur J Clin Invest. 2010;40:932-942.
34. Charmandari E, Kino T, Chrousos GP. Primary generalized familial and sporadic glucocorticoid resistance (Chrousos syndrome) and hypersensitivity. Endocr Dev. 2013;24:67-85.
35. Torpy DJ, Bachmann AW, Grice JE, et al. Familial corticosteroidbinDing globulin deficiency due to a novel null mutation: association with fatigue and relative hypotension. J Clin Endocrinol Metab. 2001;86:3692-3700.
36. Gagliardi L, Ho JT, Torpy DJ. Corticosteroid-binDing globulin: the clinical significance of altered levels and heritable mutations. Mol Cell Endocrinol. 2010;316:24-34.
37. Jones DA, Miras A, Tringham JR. Addison's disease: a diagnostic challenge. Br J Hosp Med (Lond). 2008;69:M192-M195.
38. Oelkers W, Diederich S, Bähr V. Diagnosis and therapy surveillance in Addison's disease: rapid adrenocorticotropin (ACTH) test and measurement of plasma ACTH, renin activity, and aldosterone. J Clin Endocrinol Metab. 1992;75:259-264.
39. Oelkers W. Adrenal insufficiency. NEngl J Med. 1996;335:1206-1212.
40. Lebbe M, Arlt W. What is the best diagnostic and therapeutic management strategy for an Addison patient during pregnancy? Clin Endocrinol (Oxf). 2013;78:497-502.
41. Suri D, Moran J, Hibbard JU, Kasza K, Weiss RE. Assessment of adrenal reserve in pregnancy: defining the normal response to the adrenocorticotropin stimulation test. J Clin Endocrinol Metab. 2006;91:3866-3872.
42. Jung C, Ho JT, Torpy DJ, et al. A longitudinal study of plasma and urinary cortisol in pregnancy and postpartum. J Clin Endocrinol Metab. 2011;96:1533-1540.
43. Klose M, Lange M, Rasmussen AK, et al. Factors influencing the adrenocorticotropin test: role of contemporary cortisol assays, body composition, and oral contraceptive agents. J Clin Endocrinol Metab. 2007;92:1326-1333.
44. El-Farhan N, Pickett A, Ducroq D, et al. Method-specific serum cortisol responses to the adrenocorticotrophin test: comparison of gas chromatography-mass spectrometry and five automated immunoassays. Clin Endocrinol (Oxf). 2013;78:673-680.
45. May ME, Carey RM. Rapid adrenocorticotropic hormone test in practice. Retrospective review. Am J Med. 1985;79:679-684.
46. OelkersW. The role of high-and low-dose corticotropin tests in the diagnosis of secondary adrenal insufficiency. Eur J Endocrinol. 1998;139:567-570.
47. Magnotti M, Shimshi M. Diagnosing adrenal insufficiency: which test is best-the 1-microg or the 250-microg cosyntropin stimulation test? Endocr Pract. 2008;14:233-238.
48. Dhillo WS, Kong WM, Le Roux CW, et al. Cortisol-binDing globulin is important in the interpretation of dynamic tests of the hypothalamic-pituitary-adrenal axis. Eur J Endocrinol. 2002;146: 231-235.
49. Mueller UW, Potter J. BinDing of cortisol to human albumin and serum: the effect of protein concentration. Biochem Pharmacol. 1981;30:727-733.
50. Vincent RP, Etogo-Asse FE, Dew T, Bernal W, Alaghband-Zadeh J, le Roux CW. Serum total cortisol and free cortisol index give different information regarDing the hypothalamus-pituitary-adrenal axis reserve in patients with liver impairment. Ann Clin Biochem. 2009;46:505-507.
51. le Roux CW, Chapman GA, KongWM,Dhillo WS, Jones J, Alaghband-Zadeh J. Free cortisol index is better than serum total cortisol in determining hypothalamic-pituitary-adrenal status in patients undergoing surgery. J Clin Endocrinol Metab. 2003;88:2045-2048.
52. Hamrahian AH, Oseni TS, Arafah BM. Measurements of serum free cortisol in critically ill patients. N Engl J Med. 2004;350: 1629-1638.
53. Pura M, Kreze A Jr, Kentos P, Vanuga P. The low-dose (1 microg) cosyntropin test (LDT) for primary adrenocortical insufficiency: defining the normal cortisol response and report on first patients with Addison disease confirmed with LDT. Exp Clin Endocrinol Diabetes. 2010;118:151-157.
54. Mayenknecht J, Diederich S, Bähr V, et al. Comparison of low and high dose corticotropin stimulation tests in patients with pituitary disease. J Clin Endocrinol Metab. 1998;83:1558-1562.
55. Chitale A, Musonda P, McGregor AM, Dhatariya KK. Determining the utility of the 60 min cortisol measurement in the short synacthen test. Clin Endocrinol (Oxf). 2013;79:14-19.
56. Lindholm J, Kehlet H. Re-evaluation of the clinical value of the 30 min ACTH test in assessing the hypothalamic-pituitary-adrenocortical function. Clin Endocrinol (Oxf). 1987;26:53-59.
57. Dekkers OM, Timmermans JM, Smit JW, Romijn JA, Pereira AM. Comparison of the cortisol responses to testing with two doses of ACTH in patients with suspected adrenal insufficiency. Eur J Endocrinol. 2011;164:83-87.
58. Cooper MS, Stewart PM. Corticosteroid insufficiency in acutely ill patients. N Engl J Med. 2003;348:727-734.
59. Marik PE, Pastores SM, Annane D, et al. Recommendations for the diagnosis and management of corticosteroid insufficiency in critically ill adult patients: consensus statements from an international task force by the American College of Critical Care Medicine. Crit Care Med. 2008;36:1937-1949.
60. Anantharaman R, Menezes G, Yusuf R, Ganapathi B, Ayyar SV, Srinivasan R. The 1 g cosyntropin test in normal individuals: a reappraisal. Indian J Endocrinol Metab. 2013;17:693-696.
61. Watts NB, Tindall GT. Rapid assessment of corticotropin reserve after pituitary surgery. JAMA. 1988;259:708-711.
62. Erturk E, Jaffe CA, Barkan AL. Evaluation of the integrity of the hypothalamic-pituitary-adrenal axis by insulin hypoglycemia test. J Clin Endocrinol Metab. 1998;83:2350-2354.
63. Jones SL, Trainer PJ, Perry L, Wass JA, Bessser GM, Grossman A. An audit of the insulin tolerance test in adult subjects in an acute investigation unit over one year. Clin Endocrinol (Oxf). 1994;41: 123-128.
64. Le Roux CW, Meeran K, Alaghband-Zadeh J. Is a 0900-h serum cortisol useful prior to a short Synacthen test in outpatient assessment? Ann Clin Biochem. 2002;39:148-150.
65. Endert E, Ouwehand A, Fliers E, Prummel MF, Wiersinga WM. Establishment of reference values for endocrine tests. Part IV: Adrenal insufficiency. Neth J Med. 2005;63:435-443.
66. Jenkins D, Forsham PH, Laidlaw JC, Reddy WJ, Thorn GW. Use of ACTH in the diagnosis of adrenal cortical insufficiency. Am J Med. 1955;18:3-14.
67. HäggE, Asplund K, Lithner F. Value of basal plasma cortisol assays in the assessment of pituitary-adrenal insufficiency. Clin Endocrinol (Oxf). 1987;26:221-226.
68. Baker PR, Baschal EE, Fain PR, et al. Haplotype analysis discriminates genetic risk for DR3-associated endocrine autoimmunity and helps define extreme risk for Addison's disease. J Clin Endocrinol Metab. 2010;95:E263-E270.
69. Van Rijn JL, Van Landeghem BA, Haima P, Goldschmidt HM. Evaluation of ACTH immunoradiometric assays. Clin Biochem. 1996;29:93-95.
70. Pecori Giraldi F, Saccani A, Cavagnini F. Assessment of ACTH assay variability: a multicenter study. Eur J Endocrinol. 2011;164: 505-512.
71. Saenger P, Levine LS, Irvine WJ, et al. Progressive adrenal failure in polyglandular autoimmune disease. J Clin Endocrinol Metab. 1982;54:863-867.
72. Coco G, Dal Pra C, Presotto F, et al. Estimated risk for developing autoimmune Addison's disease in patients with adrenal cortex autoantibodies. J Clin Endocrinol Metab. 2006;91:1637-1645.
73. De Bellis A, Bizzarro A, Rossi R, et al. Remission of subclinical adrenocortical failure in subjects with adrenal autoantibodies. J Clin Endocrinol Metab. 1993;76:1002-1007.
74. Betterle C, Scalici C, Presotto F, et al. The natural history of adrenal function in autoimmune patients with adrenal autoantibodies. J Endocrinol. 1988;117:467-475.
75. Rehan M, Raizman JE, Cavalier E, Don-Wauchope AC, Holmes DT. Laboratory challenges in primary aldosteronism screening and diagnosis. Clin Biochem. 2015;48:377-387.
76. Conrad K, Roggenbuck D, Reinhold D, Sack U. Autoantibody diagnostics in clinical practice. Autoimmun Rev. 2012;11:207-211.
77. Winqvist O, Karlsson FA, Kämpe O. 21-Hydroxylase, a major autoantigen in idiopathic Addison's disease. Lancet. 1992;339: 1559-1562.
78. Laureti S, De Bellis A, Muccitelli VI, et al. Levels of adrenocortical autoantibodies correlate with the degree of adrenal dysfunction in subjects with preclinical Addison's disease. J Clin Endocrinol Metab. 1998;83:3507-3511.
79. Laureti S, Aubourg P, Calcinaro F, et al. Etiological diagnosis of primary adrenal insufficiency using an original flowchart of immune and biochemical markers. J Clin Endocrinol Metab. 1998; 83:3163-3168.
80. Meager A, Visvalingam K, Peterson P, et al. Anti-interferon autoantibodies in autoimmune polyendocrinopathy syndrome type 1. PLoS Med. 2006;3:e289.
81. Laureti S, Casucci G, Santeusanio F, Angeletti G, Aubourg P, Brunetti P. X-linked adrenoleukodystrophy is a frequent cause of idiopathic Addison's disease in young adult male patients. J Clin Endocrinol Metab. 1996;81:470-474.
82. Horn MA, Erichsen MM, Wolff AS, et al. Screening for X-linked adrenoleukodystrophy among adult men with Addison's disease. Clin Endocrinol (Oxf). 2013;79:316-320.
83. Vita JA, Silverberg SJ, Goland RS, Austin JH, Knowlton AI. Clinical clues to the cause of Addison's disease. Am J Med. 1985;78: 461-466.
84. Knutsson U, Dahlgren J, Marcus C, et al. Circadian cortisol rhythms in healthy boys and girls: relationship with age, growth, body composition, and pubertal development. J Clin Endocrinol Metab. 1997;82:536-540.
85. Linder BL, Esteban NV, Yergey AL, Winterer JC, Loriaux DL, Cassorla F. Cortisol production rate in childhood and adolescence. J Pediatr. 1990;117:892-896.
86. Esteban NV, Loughlin T, Yergey AL, et al. Daily cortisol production rate in man determined by stable isotope dilution/mass spectrometry. J Clin Endocrinol Metab. 1991;72:39-45.
87. Kerrigan JR, Veldhuis JD, Leyo SA, Iranmanesh A, Rogol AD. Estimation of daily cortisol production and clearance rates in normal pubertal males by deconvolution analysis. J Clin Endocrinol Metab. 1993;76:1505-1510.
88. Purnell JQ, Brandon DD, Isabelle LM, Loriaux DL, Samuels MH. Association of 24-hour cortisol production rates, cortisol-binDing globulin, and plasma-free cortisol levels with body composition, leptin levels, and aging in adult men and women. J Clin Endocrinol Metab. 2004;89:281-287.
89. Allolio B, Winkelmann W, Fricke U, Heesen D, Kaulen D. Cortisol plasma concentration in patients with primary adrenal cortex insufficiency during substitution therapy with cortisone acetate [in German]. Verh Dtsch Ges Inn Med. 1978;84:1456-1458.
90. Czock D, Keller F, Rasche FM, Häussler U. Pharmacokinetics and pharmacodynamics of systemically administered glucocorticoids. Clin Pharmacokinet. 2005;44:61-98.
91. Plat L, Leproult R, L'Hermite-Baleriaux M, et al. Metabolic effects of short-term elevations of plasma cortisol are more pronounced in the evening than in the morning. J Clin Endocrinol Metab. 1999; 84:3082-3092.
92. Simon N, Castinetti F, Ouliac F, Lesavre N, Brue T, Oliver C. Pharmacokinetic evidence for suboptimal treatment of adrenal insufficiency with currently available hydrocortisone tablets. Clin Pharmacokinet. 2010;49:455-463.
93. Peacey SR, Guo CY, Robinson AM, et al. Glucocorticoid replacement therapy: are patients over treated and does it matter? Clin Endocrinol (Oxf). 1997;46:255-261.
94. Howlett TA. An assessment of optimal hydrocortisone replacement therapy. Clin Endocrinol (Oxf). 1997;46:263-268.
95. Mah PM, Jenkins RC, Rostami-Hodjegan A, et al. Weight-related dosing, timing and monitoring hydrocortisone replacement therapy in patients with adrenal insufficiency. Clin Endocrinol (Oxf). 2004;61:367-375.
96. Laureti S, Falorni A, Santeusanio F. Improvement of treatment of primary adrenal insufficiency by administration of cortisone acetate in three daily doses. J Endocrinol Invest. 2003;26:1071-1075.
97. Barbetta L, Dall'Asta C, Re T, Libè R, Costa E, Ambrosi B. Comparison of different regimens of glucocorticoid replacement therapy in patients with hypoadrenalism. J Endocrinol Invest. 2005; 28:632-637.
98. Ekman B, Bachrach-Lindström M, Lindström T, Wahlberg J, Blomgren J, Arnqvist HJ. A randomized, double-blind, crossover study comparing two-and four-dose hydrocortisone regimen with regard to quality of life, cortisol andACTHprofiles in patients with primary adrenal insufficiency. Clin Endocrinol (Oxf). 2012;77: 18-25.
99. Alonso N, Granada ML, Lucas A, et al. Evaluation of two replacement regimens in primary adrenal insufficiency patients. Effect on clinical symptoms, health-related quality of life and biochemical parameters. J Endocrinol Invest. 2004;27:449-454.
100. Forss M, Batcheller G, Skrtic S, Johannsson G. Current practice of glucocorticoid replacement therapy and patient-perceived health outcomes in adrenal insufficiency-a worldwide patient survey. BMC Endocr Disord. 2012;12:8.
101. Fariss BL, Hane S, Shinsako J, Forsham PH. Comparison of absorption of cortisone acetate and hydrocortisone hemisuccinate. J Clin Endocrinol Metab. 1978;47:1137-1140.
102. Filipsson H, Monson JP, Koltowska-Häggström M, Mattsson A, Johannsson G. The impact of glucocorticoid replacement regimens on metabolic outcome and comorbidity in hypopituitary patients. J Clin Endocrinol Metab. 2006;91:3954-3961.
103. Fadeev VV, Gitel EP, Mel'nichenko GA. The diurnal rhythm of adrenocorticotropic hormone secretion in the assessment of the adequacy of replacement therapy in primary chronic adrenal failure. Neurosci Behav Physiol. 2001;31:237-242.
104. Johannsson G, Nilsson AG, Bergthorsdottir R, et al. Improved cortisol exposure-time profile and outcome in patients with adrenal insufficiency: a prospective randomized trial of a novel hydrocortisone dual-release formulation. J Clin Endocrinol Metab. 2012;97:473-481.
105. Williams GH, Cain JP, Dluhy RG, Underwood RH. Studies of the control of plasma aldosterone concentration in normal man. I. Response to posture, acute and chronic volume depletion, and sodium loading. J Clin Invest. 1972;51:1731-1742.
106. Miller WL, Auchus RJ. The molecular biology, biochemistry, and physiology of human steroidogenesis and its disorders. Endocr Rev. 2011;32:81-151.
107. Oelkers W, L'Age M. Control of mineralocorticoid substitution in Addison's disease by plasma renin measurement. Klin Wochenschr. 1976;54:607-612.
108. Flad TM, Conway JD, Cunningham SK, McKenna TJ. The role of plasma renin activity in evaluating the adequacy of mineralocorticoid replacement in primary adrenal insufficiency. Clin Endocrinol (Oxf). 1996;45:529-534.
109. Methlie P, Husebye EE, Hustad S, Lien EA, Løvås K. Grapefruit juice and licorice increase cortisol availability in patients with Addison's disease. Eur J Endocrinol. 2011;165:761-769.
110. Keilholz U, Guthrie GP Jr. Adverse effect of phenytoin on mineralocorticoid replacement with fludrocortisone in adrenal insufficiency. Am J Med Sci. 1986;291:280-283.
111. Ross IL, Bergthorsdottir R, Levitt N, et al. Cardiovascular risk factors in patients with Addison's disease: a comparative study of South African and Swedish patients. PLoS One. 2014;9:e90768.
112. Inder WJ, Meyer C, Hunt PJ. Management of hypertension and heart failure in patients with Addison's disease. Clin Endocrinol (Oxf). 2015;82:789-792.
113. Orentreich N, Brind JL, Rizer RL, Vogelman JH. Age changes and sex differences in serum dehydroepiandrosterone sulfate concentrations throughout adulthood. J Clin Endocrinol Metab. 1984; 59:551-555.
114. Arlt W, Callies F, van Vlijmen JC, et al. Dehydroepiandrosterone replacement in women with adrenal insufficiency. N Engl J Med. 1999;341:1013-1020.
115. Hunt PJ, Gurnell EM, Huppert FA, et al. Improvement in mood and fatigue after dehydroepiandrosterone replacement in Addison's disease in a randomized, double blind trial. J Clin Endocrinol Metab. 2000;85:4650-4656.
116. Christiansen JJ, Bruun JM, Christiansen JS, Jørgensen JO, Gravholt CH. Long-term DHEA substitution in female adrenocortical failure, body composition, muscle function, and bone metabolism: a randomized trial. Eur J Endocrinol. 2011;165:293-300.
117. Alkatib AA, Cosma M, Elamin MB, et al. A systematic review and meta-analysis of randomized placebo-controlled trials of DHEA treatment effects on quality of life in women with adrenal insufficiency. J Clin Endocrinol Metab. 2009;94:3676-3681.
118. Binder G, Weber S, Ehrismann M, et al. Effects of dehydroepiandrosterone therapy on pubic hair growth and psychological well-being in adolescent girls and young women with central adrenal insufficiency: a double-blind, randomized, placebo-controlled phase III trial. J Clin Endocrinol Metab. 2009;94:1182-1190.
119. Allolio B, Hoffmann J, Linton EA, Winkelmann W, Kusche M, Schulte HM. Diurnal salivary cortisol patterns during pregnancy and after delivery: relationship to plasma corticotrophin-releasinghormone. Clin Endocrinol (Oxf). 1990;33:279-289.
120. Hahner S, Loeffler M, Bleicken B, et al. Epidemiology of adrenal crisis in chronic adrenal insufficiency: the need for new prevention strategies. Eur J Endocrinol. 2010;162:597-602.
121. Zelissen PM, Croughs RJ, van Rijk PP, Raymakers JA. Effect of glucocorticoid replacement therapy on bone mineral density in patients with Addison disease. Ann Intern Med. 1994;120:207-210.
122. Bancos I, Hahner S, Tomlinson J, Arlt W. Diagnosis and management of adrenal insufficiency. Lancet Diabetes Endocrinol. 2015; 3:216-226.
123. Wiegand S, Richardt A, Remer T, et al. Reduced 11α-hydroxysteroid dehydrogenase type 1 activity in obese boys. Eur J Endocrinol. 2007;157:319-324.
124. Bonfig W, Pozza SB, Schmidt H, Pagel P, Knorr D, Schwarz HP. Hydrocortisone dosing during puberty in patients with classical congenital adrenal hyperplasia: an evidence-based recommendation. J Clin Endocrinol Metab. 2009;94:3882-3888.
125. Grigorescu-Sido A, BettendorfM,Schulze E, Duncea I, Heinrich U. Growth analysis in patients with 21-hydroxylase deficiency influence of glucocorticoid dosage, age at diagnosis, phenotype and genotype on growth and height outcome. Horm Res. 2003; 60:84-90.
126. Allolio B. Extensive expertise in endocrinology: adrenal crisis. Eur J Endocrinol. 2015;172:R115-R124.
127. White K, Arlt W. Adrenal crisis in treated Addison's disease: a predictable but under-managed event. Eur J Endocrinol. 2010; 162:115-120.
128. Hahner S, Spinnler C, FassnachtM,et al. High incidence of adrenal crisis in educated patients with chronic adrenal insufficiency: a prospective study. J Clin Endocrinol Metab. 2015;100:407-416.
129. Reisch N, Willige M, Kohn D, et al. Frequency and causes of adrenal crises over lifetime in patients with 21-hydroxylase deficiency. Eur J Endocrinol. 2012;167:35-42.
130. Fonseca V, Brown R, Hochhauser D, Ginsburg J, Havard CW. Acute adrenal crisis precipitated by thyroxine. Br Med J (Clin Res Ed). 1986;292:1185-1186.
131. Chortis V, Taylor AE, Schneider P, et al. Mitotane therapy in adrenocortical cancer induces CYP3A4 and inhibits 5-reductase, explaining the need for personalized glucocorticoid and androgen replacement. J Clin Endocrinol Metab. 2013;98:161-171.
132. Goldfien A, Laidlaw JC, Haydar NA, Renold AE, Thorn GW. Fluorohydrocortisone and chlorohydrocortisone, highly potent derivatives of compound F. N Engl J Med. 1955;252:415-421.
133. Renold AE, Haydar NA, Reddy WJ, Goldfien A, St Marc JR, Laidlaw JC. Biological effects of fluorinated derivatives of hydrocortisone and progesterone in man. Ann NY Acad Sci. 1955;61:582-590.
134. Thorn GW, Renold AE, Morse WI, Goldfien A, Reddy WJ. Highly potent adrenal cortical steroids: structure and biological activity. Ann Intern Med. 1955;43:979-1000.
135. Weise M, Drinkard B, Mehlinger SL, et al. Stress dose of hydrocortisone is not beneficial in patients with classic congenital adrenal hyperplasia undergoing short-term, high-intensity exercise. J Clin Endocrinol Metab. 2004;89:3679-3684.
136. Quinkler M, Hahner S. What is the best long-term management strategy for patients with primary adrenal insufficiency? Clin Endocrinol (Oxf). 2012;76:21-25.
137. Chernow B, Alexander HR, Smallridge RC, et al. Hormonal responses to graded surgical stress. Arch Intern Med. 1987;147: 1273-1278.
138. Udelsman R, Norton JA, Jelenich SE, et al. Responses of the hypothalamic-pituitary-adrenal and renin-angiotensin axes and the sympathetic system during controlled surgical and anesthetic stress. J Clin Endocrinol Metab. 1987;64:986-994.
139. Rains PC, Rampersad N, De Lima J, et al. Cortisol response to general anaesthesia for medical imaging in children. Clin Endocrinol (Oxf). 2009;71:834-839.
140. HsuAA,von Elten K,ChanD, et al. Characterization of the cortisol stress response to sedation and anesthesia in children. J Clin Endocrinol Metab. 2012;97:E1830-E1835.
141. Taylor LK, Auchus RJ, Baskin LS, Miller WL. Cortisol response to operative stress with anesthesia in healthy children. J Clin Endocrinol Metab. 2013;98:3687-3693.
142. Sapolsky RM, Romero LM, Munck AU. How do glucocorticoids influence stress responses? Integrating permissive, suppressive, stimulatory, and preparative actions. Endocr Rev. 2000;21: 55-89.
143. Koniaris LG, Wand G, Wright TM. TNF mediates a murine model of Addison's crisis. Shock. 2001;15:29-34.
144. Salem M, Tainsh RE Jr, Bromberg J, Loriaux DL, Chernow B. Perioperative glucocorticoid coverage. A reassessment 42 years after emergence of a problem. Ann Surg. 1994;219:416-425.
145. Glowniak JV, Loriaux DL. A double-blind study of perioperative steroid requirements in secondary adrenal insufficiency. Surgery. 1997;121:123-129.
146. Boonen E, Vervenne H, Meersseman P, et al. Reduced cortisol metabolism during critical illness. NEngl J Med. 2013;368:1477-1488.
147. Hahner S, Burger-Stritt S, Allolio B. Subcutaneous hydrocortisone administration for emergency use in adrenal insufficiency. Eur J Endocrinol. 2013;169:147-154.
148. Hahner S, Hemmelmann N, Quinkler M, Beuschlein F, Spinnler C, Allolio B. Timelines in the management of adrenal crisis-targets, limits and reality. Clin Endocrinol (Oxf). 2015;82:497-502.
149. Bergthorsdottir R, Leonsson-Zachrisson M, Odén A, Johannsson G. Premature mortality in patients with Addison's disease: a population-based study. J Clin Endocrinol Metab. 2006;91:4849-4853.
150. Bensing S, Brandt L, Tabaroj F, et al. Increased death risk and altered cancer incidence pattern in patients with isolated or combined autoimmune primary adrenocortical insufficiency. Clin Endocrinol (Oxf). 2008;69:697-704.
151. Repping-Wuts HJ, Stikkelbroeck NM, Noordzij A, Kerstens M, Hermus AR. A glucocorticoid education group meeting: an effective strategy for improving self-management to prevent adrenal crisis. Eur J Endocrinol. 2013;169:17-22.
152. Harsch IA, Schuller A, Hahn EG, Hensen J. Cortisone replacement therapy in endocrine disorders-quality of self-care. J Eval Clin Pract. 2010;16:492-498.
153. Braatvedt GD, Newrick PG, Corrall RJ. Patients' self administration of hydrocortisone. BMJ. 1990;301:1312.
154. Fleming LK, Rapp CG, Sloane R. Caregiver knowledge and selfconfidence of stress dosing of hydrocortisone in children with congenital adrenal hyperplasia. J Pediatr Nurs. 2011;26:e55-e60.
155. Quinkler M, Dahlqvist P, Husebye ES, Kämpe O. A European Emergency Card for adrenal insufficiency can save lives. Eur J Intern Med. 2015;26:75-76.
156. Fichna M, Fichna P, Gryczyn ska M, et al. Screening for associated autoimmune disorders in Polish patients with Addison's disease. Endocrine. 2010;37:349-360.
157. Zelissen PM, Bast EJ, Croughs RJ. Associated autoimmunity in Addison's disease. J Autoimmun. 1995;8:121-130.
158. Betterle C, Scarpa R, Garelli S, et al. Addison's disease: a survey on 633 patients in Padova. Eur J Endocrinol. 2013;169:773-784.
159. Reato G, Morlin L, Chen S, et al. Premature ovarian failure in patients with autoimmune Addison's disease: clinical, genetic, and immunological evaluation. J Clin Endocrinol Metab. 2011;96: E1255-E1261.
160. Winqvist O, Gustafsson J, Rorsman F, Karlsson FA, Kämpe O. Two different cytochrome P450 enzymes are the adrenal antigens in autoimmune polyendocrine syndrome type I and Addison's disease. J Clin Invest. 1993;92:2377-2385.
161. Falorni A, Brozzetti A, Aglietti MC, et al. Progressive decline of residual follicle pool after clinical diagnosis of autoimmune ovarian insufficiency. Clin Endocrinol (Oxf). 2012;77:453-458.
162. Myhre AG, Aarsetøy H, Undlien DE, Hovdenak N, Aksnes L, Husebye ES. High frequency of coeliac diseaseamongpatients with autoimmune adrenocortical failure. Scand J Gastroenterol. 2003; 38:511-515.
163. Betterle C, Lazzarotto F, Spadaccino AC, et al. Celiac disease in North Italian patients with autoimmune Addison's disease. Eur J Endocrinol. 2006;154:275-279.
164. Charmandari E, Nicolaides NC, Chrousos GP. Adrenal insufficiency. Lancet. 2014;383:2152-2167.
165. Raff H. Utility of salivary cortisol measurements in Cushing's syndrome and adrenal insufficiency. J Clin Endocrinol Metab. 2009; 94:3647-3655.
166. Keevil BG. Novel liquid chromatography tandem mass spectrometry (LC-MS/MS) methods for measuring steroids. Best Pract Res Clin Endocrinol Metab. 2013;27:663-674.
167. Giordano R, Marzotti S, Balbo M, et al. Metabolic and cardiovascular profile in patients with Addison's disease under conventional glucocorticoid replacement. J Endocrinol Invest. 2009;32: 917-923.
168. Bornstein SR, Breidert M, Ehrhart-Bornstein M, Kloos B, ScherbaumWA. Plasma catecholamines in patients with Addison's disease. Clin Endocrinol (Oxf). 1995;42:215-218.
169. Merke DP, Chrousos GP, Eisenhofer G, et al. Adrenomedullary dysplasia and hypofunction in patients with classic 21-hydroxylase deficiency. N Engl J Med. 2000;343:1362-1368.
170. Newell-Price J, Whiteman M, Rostami-Hodjegan A, et al. Modified-release hydrocortisone for circadian therapy: a proof-of-principle study in dexamethasone-suppressed normal volunteers. Clin Endocrinol (Oxf). 2008;68:130-135.
171. Mallappa A, Sinaii N, Kumar P, et al. A phase 2 study of Chronocort, a modified-release formulation of hydrocortisone, in the treatment of adults with classic congenital adrenal hyperplasia. J Clin Endocrinol Metab. 2015;100:1137-1145.
172. Løvås K, Husebye ES. Continuous subcutaneous hydrocortisone infusion in Addison's disease. Eur J Endocrinol. 2007;157:109-112.
173. Oksnes M, Björnsdottir S, Isaksson M, et al. Continuous subcutaneous hydrocortisone infusion versus oral hydrocortisone replacement for treatment of Addison's disease: a randomized clinical trial. J Clin Endocrinol Metab. 2014;99:1665-1674.
174. Gagliardi L, Nenke MA, Thynne TR, et al. Continuous subcutaneous hydrocortisone infusion therapy in Addison's disease: a randomized, placebo-controlled clinical trial. J Clin Endocrinol Metab. 2014;99:4149-4157.
175. Russell GM, Durant C, Ataya A, et al. Subcutaneous pulsatile glucocorticoid replacement therapy. Clin Endocrinol (Oxf). 2014;81: 289-293.
176. Pearce SH, Mitchell AL, Bennett S, et al. Adrenal steroidogenesis after B lymphocyte depletion therapy in new-onset Addison's disease. J Clin Endocrinol Metab. 2012;97:E1927-E1932.
177. Gan EH, MacArthur K, Mitchell AL, et al. Residual adrenal function in autoimmune Addison's disease: improvement after tetracosactide (ACTH1-24) treatment. J Clin Endocrinol Metab. 2014; 99:111-118.
178. Tajima T, Okada T,MaXM, Ramsey W, Bornstein S, Aguilera G. Restoration of adrenal steroidogenesis by adenovirus-mediated transfer of human cytochrome P450 21-hydroxylase into the adrenal gland of 21-hydroxylase-deficient mice. Gene Ther. 1999;6: 1898-1903.
179. Grodstein E, Hardy MA, Goldstein MJ. A case of human intramuscular adrenal gland transplantation as a cure for chronic adrenal insufficiency. Am J Transplant. 2010;10:431-433.
180. Ludwig B, Reichel A, Steffen A, et al. Transplantation of human islets without immunosuppression. Proc Natl Acad SciUSA. 2013; 110:19054-19058.
181. Husebye ES, Allolio B, Arlt W, et al. Consensus statement on the diagnosis, treatment and follow-up of patients with primary adrenal insufficiency. J Intern Med. 2014;275:104-115.